The purpose of this trial is to assess the effect of two Intensive Outpatient Management
Strategies (IOMS) versus Routine Care (RC) on the outcomes of patients with Rheumatoid
Arthritis (RA) that are treated with adalimumab.
This is a multi-center, randomized, controlled, parallel group, single (patient) blind trial.
A total of 300 patients (100 per group) with RA will be recruited from approximately 40 sites